SCHEMBL13866137

SCHEMBL13866137

C=CCOc1cccc2c1nc(-c1cccc(C(=O)OC)c1F)c(=O)n2COCC[Si](C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ BLM P54132 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ LIG1 P18858 1/20 0.32
▸ ADRB2 P07550 1/20 0.31
▸ ADRB1 P08588 1/20 0.31
▸ ADRB3 P13945 1/20 0.31
▸ DGAT1 O75907 1/20 0.31
▸ MAP4K1 Q92918 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ FGFR1 P11362 1/20 0.30
▸ FGFR4 P22455 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13865869 0.91 ALDH1A1 (0.38) ALDH1A1NPC1KDM4EDGAT1MAP4K1
SCHEMBL13866135 0.85 NPC1 (0.39) ALDH1A1NPC1KDM4EMAP4K1SLC6A4
SCHEMBL13866116 0.85 NPC1 (0.41) ALDH1A1NPC1KDM4EMAP4K1SLC6A4
SCHEMBL13866138 0.84 NPC1 (0.35) NPC1KDM4EMAP4K1MEN1KMT2A
SCHEMBL13866139 0.83 NPC1 (0.33) NPC1KDM4E
SCHEMBL5669071 0.82 NPC1 (0.38) NPC1MAPT
SCHEMBL5667295 0.82 CFTR (0.43) ALDH1A1NPC1KDM4EMAPTLMNA
SCHEMBL13866115 0.82 CFTR (0.39) ALDH1A1NPC1KDM4EMAPTLMNA
SCHEMBL13865949 0.81 NPC1 (0.35) ALDH1A1NPC1KDM4EDGAT1MAPT
SCHEMBL13870973 0.79 NPC1 (0.37) ALDH1A1NPC1DGAT1SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137597-A1 Novel quinoxalinone derivatives MSD K.K. (JP) 2009-05-28 — — US disclosed
US-7388010-B2 Quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137597-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB7 ALDH1A1 975/4885NPC1 1218/4885KDM4E 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback